CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Kirsten R. Müller-Vahl

OPENALEX: A5010766574↗ORCID: 0000-0002-7181-7419↗

Affiliations

Organizations

International Association for Psychoanalytic Self Psychologyauthorship · US Medizinische Hochschule Hannoverauthorship · DE Nova Institutauthorship · DE

Public evidence

6 connected articles

The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment.2025 · Europe PMC Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process.2021 · Europe PMC European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.2021 · PubMed Central Open Access Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome.2020 · Europe PMC The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders.2020 · Europe PMC Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients.2017 · Europe PMC

Registered research

Connected studies

A Randomized Multi-centre Double-blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disordersnct03087201

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.

Kirsten R. Müller-Vahl - Medical Cannabis Research Engine